Werewolf Therapeutics (HOWL) Return on Sales (2022 - 2025)
Werewolf Therapeutics (HOWL) has disclosed Return on Sales for 4 consecutive years, with 4861.73% as the latest value for Q3 2025.
- On a quarterly basis, Return on Sales fell 484390.0% to 4861.73% in Q3 2025 year-over-year; TTM through Sep 2025 was 4861.73%, a 484390.0% decrease, with the full-year FY2024 number at 37.67%, down 3586.0% from a year prior.
- Return on Sales was 4861.73% for Q3 2025 at Werewolf Therapeutics, up from 4888.4% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.63% in Q2 2023 to a low of 4888.4% in Q2 2025.
- A 4-year average of 802.97% and a median of 11.21% in 2023 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: soared 296bps in 2023, then tumbled -487238bps in 2025.
- Werewolf Therapeutics' Return on Sales stood at 1.65% in 2022, then tumbled by -288bps to 6.4% in 2023, then tumbled by -21068bps to 1353.73% in 2024, then tumbled by -259bps to 4861.73% in 2025.
- Per Business Quant, the three most recent readings for HOWL's Return on Sales are 4861.73% (Q3 2025), 4888.4% (Q2 2025), and 63.59% (Q1 2025).